Welcome to our dedicated page for Anika Therapeutics SEC filings (Ticker: ANIK), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Anika Therapeutics, Inc. filings document the regulatory record of a Nasdaq-listed orthopedic products company centered on hyaluronic-acid-based OA Pain Management and Regenerative Solutions. Its 8-K filings report operating and financial results, guidance updates, material events, clinical and regulatory disclosures for Hyalofast, and governance matters involving board and executive transitions.
Proxy materials describe shareholder voting matters, board structure, executive compensation, corporate governance practices, and the company’s focused portfolio following completed portfolio actions. The filings also identify ANIK common stock, capital-structure disclosures, risk and operating topics, and channel-based business reporting for Commercial Channel and OEM Channel activity.
Anika Therapeutics, Inc. (ANIK) Form 4 filing: Director Gary P. Fischetti reported the award of 14,164 restricted stock units (RSUs) on 20 June 2025. Each RSU converts into one common share at no cost to the director and will vest in full on the earlier of the company’s 2026 annual shareholder meeting or 20 June 2026. Following the grant, Fischetti’s total beneficial ownership increases to 41,613 common shares, held directly. No open-market purchases or sales were reported, and no derivative securities were exercised or disposed of.
Form 4 snapshot: On 06/20/2025, Anika Therapeutics, Inc. (ANIK) director Sheryl L. Conley received an equity grant of 14,164 restricted stock units (RSUs) at no cost. The award lifts her beneficial ownership to 42,568 common shares following the transaction.
The RSUs will vest in full on the earlier of the 2026 annual shareholder meeting or June 20, 2026, providing a one-year vesting horizon. Each RSU converts into one share of ANIK common stock upon vesting, subject to continued service. No derivative securities or open-market purchases/sales were reported, and no 10b5-1 trading plan was indicated.
This filing reflects routine director compensation rather than a discretionary purchase. The share amount is modest relative to ANIK’s 14 million-plus outstanding shares and therefore is unlikely to materially affect the company’s capital structure or near-term valuation. Nevertheless, it marginally strengthens director-level alignment with shareholder interests by increasing Conley’s equity stake.
Insider transaction overview – Anika Therapeutics, Inc. (ANIK)
On 20 June 2025, director Joseph H. Capper filed a Form 4 disclosing the award of 14,164 restricted stock units (RSUs) under transaction code “A” (award/grant). The grant was made at $0 cost; no open-market cash purchase occurred.
After the award, Capper’s total beneficial ownership rose to 20,403 common shares. The RSUs convert to common stock on a 1-for-1 basis and vest in full on the earlier of the 2026 annual shareholder meeting or 20 June 2026, thereby tying compensation to medium-term company performance.
No derivative positions, sales, or additional acquisitions were reported, and the filing contains no financial performance data. The transaction appears to be a routine board-related equity grant that modestly strengthens alignment between the director and shareholders without signaling market sentiment through cash purchases.
Anika Therapeutics held its Annual Meeting on June 20, 2025, with 86.13% shareholder participation (12.35M shares represented). Key outcomes include:
- Board Elections: Three Class II directors elected until 2028 - Cheryl Blanchard, Joseph Capper, and Glenn Larsen, with Capper receiving strongest support (10.5M votes)
- 2017 Omnibus Incentive Plan Amendment: Shareholders approved increasing reserved shares by 475,000 to total 5.76M shares. All shares may be granted as incentive stock options under IRC Section 422
- Other Approvals: Shareholders ratified Deloitte & Touche as independent auditor (12.07M votes in favor) and approved executive compensation in advisory vote (8.37M votes in favor)
The meeting demonstrated strong shareholder engagement, though some proposals like executive compensation and incentive plan amendment faced notable opposition with over 2.5M votes against each.